300601 康泰生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.3460.7292.1009.298-1.462
总资产报酬率 ROA (%)0.2370.4911.3605.966-0.950
投入资产回报率 ROIC (%)0.2830.5891.6587.268-1.127

边际利润分析
销售毛利率 (%)71.09874.68881.99684.53884.166
营业利润率 (%)6.4391.4246.83427.288-10.058
息税前利润/营业总收入 (%)9.9633.3086.63326.996-11.383
净利润/营业总收入 (%)5.3242.6297.60124.768-4.203

收益指标分析
经营活动净收益/利润总额(%)79.462369.978233.61796.559-159.565
价值变动净收益/利润总额(%)19.34014.9521.2310.201-1.218
营业外收支净额/利润总额(%)-1.72216.265-20.867-0.9146.113

偿债能力分析
流动比率 (X)2.8712.7062.3581.9612.212
速动比率 (X)2.5362.3982.0621.6801.901
资产负债率 (%)30.89631.66933.66436.74934.824
带息债务/全部投入资本 (%)14.80715.04716.35618.46217.870
股东权益/带息债务 (%)554.895543.268487.710423.035437.893
股东权益/负债合计 (%)223.663215.773197.058172.118187.155
利息保障倍数 (X)2.7422.0596.777-601.93216.989

营运能力分析
应收账款周转天数 (天)380.457361.658378.411262.999213.998
存货周转天数 (天)339.176389.436586.514502.381643.025